The discovery of a new drug class for the acute treatment of migraine

Headache

Volumn 47, Issue SUPPL. 1, 2007, Pages

  Humphrey, Patrick P A ^a  

^a THERAVANCE INC   (United States)

Author keywords

Adenosine A1 receptors; Serotonin receptors; Somatostatin sst2; Sumatriptan; Triptans

Indexed keywords

6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; ADENOSINE A1 RECEPTOR; AH 24167; AH 25086; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE; ERGOTAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; METHYSERGIDE; OCTREOTIDE; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SOMATOSTATIN RECEPTOR 2; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG;

ACROMEGALY; BRAIN BLOOD FLOW; BRAIN CIRCULATION; CAROTID ARTERY FLOW; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEADACHE; HUMAN; LOW DRUG DOSE; MIGRAINE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIGEMINAL NERVE; VASOCONSTRICTION; VASODILATATION;

GTP-BINDING PROTEINS; HISTORY, 20TH CENTURY; HUMANS; MIGRAINE DISORDERS; RECEPTORS, SEROTONIN; SEROTONIN; TRYPTAMINES;

EID: 34247115575     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.00672.x     Document Type: Conference Paper

References (46)

1. Goodell H. Thirty years of headache research in the laboratory of the lateDr. Harold G. Wolff. Headache. 1967;6:158-171.
2. Wolff HG. Man's nervous system and disease. Arch Neurol. 1961;5:235-243.
3. Dalessio DJ. Remembrance of Dr. Harld G. Wolff. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's Headache and Other Headache Pain, 7th ed. Oxford, UK: Oxford University Press; 2001:3-5.
4. Graham JR, Wolff HG. Mechanisms of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938;39:737-763.
5. Drummond PD, Lance JW. Extracranial vascular changes and the source of pain in migraine headache. Ann Neurol. 1983;13:32-37.
6. Lance JW. The Mechanism and Management of Headache, 2nd ed. London, UK: Butterworths; 1973.
7. Ostfeld AM, Wolff HG. Studies on headache: Arterenol (norepinephrine) and vascular headache of the migraine type. Arch Neurol Psychiatry. 1955;74:131-136.
8. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology. 1960;10:107-111.
9. Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol. 1967;16:544-552.
10. Curran DA, Hinterberger H, Lance JW. Total plasma serotonin, 5-hydroxyindoleacetic acid and phydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain. 1965;88:997-1010.
11. Sicuteri F, Testi A, Anselmi B. Biochemical investigation in headache: Increase in the hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy Appl Immunol. 1961;19:55-58.
12. Lance JW, Anthony M, Somerville B. Comparative trial of serotonin antagonists in the management of migraine. Br Med J. 1970;1:327-330.
13. Saxena PR. Selective vasoconstriction in carotid vascular bed by methysergide: Possible relevance to its antimigraine effect. Eur J Pharmacol. 1974;27:99-105.
14. Humphrey PP, Apperly E, Feniuk W, Perren MJ. A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena PR, Wallis DI, Wouters W, Bevan P, eds. Cardiovascular Pharmacology of 5-Hydroxytryptamine. Dordrecht: Kluwer Academic Publishers; 1990:417-431.
15. Apperley E, Feniuk W, Humphrey PP, Levy GP. Evidence for two types of excitatory receptor for 5-hydroxytryptamine in dog isolated vasculature. Br J Pharmacol. 1980;68:215-224.
16. 1-like receptor in dog isolated saphenous vein. Br J Pharmacol. 1988;94:1123-1132.
17. 1-like receptor agonist GR43175. Cephalalgia. 1989;9(suppl 9):23-33.
18. Feniuk W, Humphrey PP, Perren MJ. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetised dogs. Br J Pharmacol. 1989;96:83-90.
19. Perren MJ, Feniuk W, Humphrey PP. The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175. Cephalalgia. 1989;9(suppl 9):41-46.
20. 1-like receptor agonists for a vascular aetiology. In: Sandler M, Collins GM, eds. Migraine: A Spectrum of Ideas. Oxford, UK: Oxford University Press; 1990:147-172.
21. Heyck H. Vascular shunt mechanisms and migraine pathogenesis. Neurology. 1981;31:1203-1204.
22. Humphrey PPA. The discovery of sumatriptan and a new class of drug for the acute treatment of migraine. In: Humphrey P, Ferrari M, Olesen J, eds. The Triptans: Novel Drugs for Migraine. Oxford, NY: Oxford University Press; 2001:1-10.
23. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325:316-321.
24. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265:2831-2835.
25. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: Effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia. 1988;8:83-91.
26. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol. 1990;99:202-206.
27. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech. 2001;53:167-178.
28. Edvinsson L, Goadsby PJ. Neuropeptides in the cerebral circulation: Relevance to headache. Cephalalgia. 1995;15:272-276.
29. Humphrey PP, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci. 1991;12:444-446.
30. Nichols FT 3rd, Mawad M, Mohr JP, Stein B, Hilal S, Michelsen WJ. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke. 1990;21:555-559.
31. Friberg L, Olesen J, Iversen HK, Sperling B. Migraine pain associated withmiddle cerebral artery dilatation: Reversal by sumatriptan. Lancet. 1991;338:13-17.
32. Hoskin KL, Kaube H, Goadsby PJ. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain. 1996;119(Pt 5):1419-1428.
33. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol. 1993;109:788-792.
34. Goadsby PJ, Knight Y. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors. Br J Pharmacol. 1997;122:918-922.
35. Gomez-Mancilla B, Cutler NR, Leibowitz MT, et al. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia. 2001;21:727-732.
36. 1F receptor agonists in acute migraine treatment: A hypothesis. Cephalalgia. 2003;23:776-785.
37. Feniuk W, Humphrey PPA. The importance of vasoconstriction in the mechanism of the anti-migraine action of the triptans. In: Humphrey P, Ferrari M, Olesen J, eds. The Triptans: Novel Drugs for Migraine. Oxford, NY: Oxford University Press; 2001: 125-133.
38. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996;384:560-564.
39. Burstein R, Yamamura H, Malick A, Strassman AM. Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons. J Neurophysiol. 1998;79:964-982.
40. 1B/1D agonist. Br J Pharmacol. 1999;126:1478-1486.
41. Humphrey PPA. Somatostatin receptor activation and analgesia. In: Sandler M, Ferrari M, Harnett S, eds. Migraine: Pharmacology and Genetics. Chapman and Hall; 1996:222-232.
42. Selmer I, Schindler M, Allen JP, Humphrey PP, Emson PC. Advances in understanding neuronal somatostatin receptors. Regul Pept. 2000;90:1-18.
43. Kapicioglu S, Gokce E, Kapicioglu Z, Ovali E. Treatment of migraine attacks with a long-acting somatostatin analogue (octreotide, SMS 201-995). Cephalalgia. 1997;17:27-30.
44. Schindler M, Harris CA, Hayes B, Papotti M, Humphrey PP. Immunohistochemical localization of adenosine A1 receptors in human brain regions. Neurosci Lett. 2001;297:211-215.
45. Carruthers AM, Sellers LA, Jenkins DW, Jarvie EM, Feniuk W, Humphrey PP. Adenosine A(1) receptor-mediated inhibition of protein kinese A-induced calcitonin gene-related peptide release from rat trigeminal neurons. Mol Pharmacol. 2001;59:1533-1541.
46. Una McGovern, ed. Webster's NewWorld Dictionary of Quotations. Hoboken, NJ: Wiley Publishing, Inc.; 2005:642.